Sponsored content brought to you by

Pharmacosmos Logo


The landscape of cell and gene therapies has rapidly evolved in recent years, with a continuous flow of discoveries and new protocols being developed. There is an increasing demand to prioritize the health of cells during and after cryopreservation, which has spurred the need for DMSO-free and reduced toxicity cryopreservation media. In response, Pharmacosmos has developed PentaHibe®, a new range of cryoprotective formulas that are DMSO-free or contain a significantly reduced amount of DMSO.

Pharmacosmos is recognized for its excellence in pharmaceutical production, meeting the highest standards of quality and safety. The company’s dedication to innovation and its strict adherence to cGMP standards for human medicines underscore its commitment to provide safe and effective solutions across various applications.

The development of PentaHibe is a direct response to the need for specialized cryopreservation solutions in the cell and gene therapy sectors. This line of carbohydrate-based cryoprotection formulas, featuring Pharmacosmos’ patented key component, pentaisomaltose, is a testament to the company’s innovative approach. Pentaisomaltose is a non-penetrating cryoprotectant agent (CPA) that stabilizes the cell wall during cryopreservation without interacting with the cell’s internal structure. This natural component is easily degraded in the body to glucose, ensuring a high safety profile.

Pharmacosmos' PentaHibePentaHibe has demonstrated its efficacy in achieving comparable post-thaw viability results to commercial media containing 10% DMSO in various cell types, including T cells, mesenchymal cells, and hematopoietic stem and progenitor cells. PentaHibe is available in a variety of formulations to enable customers to optimize results for their cell products.

The recently introduced formulation, PentaHibe Complete, contains 10% pentaisomaltose and 2% DMSO as cryoprotective agents. It offers the convenience of a ready-to-use solution with reductions in toxicity and in side effects associated with DMSO, while maintaining or surpassing the viability, recovery, and proliferation rates of traditional cryopreservation formulations.

For those seeking a customizable solution, PentaHibe Base (40% pentaisomaltose) provides a versatile, DMSO-free option that can be used as it is or diluted into media of choice. PentaHibe is also available in an easy-to-use, adaptable option for large-scale production, ensuring that Pharmacosmos’ solutions cater to the diverse requirements of the cell therapy industry.

Pharmacosmos supports its customers with comprehensive resources, including detailed media protocols for various cell types, safety data sheets, and scientific assistance from a team of experienced investigators and scientists.




For more information on optimizing cryopreservation practices with PentaHibe solutions, visit www.pentahibe.com.

Previous articleThe Emerging Role of ssDNA in Gene Therapy
Next articleOrganoid-Immune Co-Culture Models for Cancer Research